← Back to Search

Cell-free DNA Testing for Lymphoma

N/A

Recruiting

Led By Christopher Flowers, MD

Research Sponsored by M.D. Anderson Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion; an average 1 year

Awards & highlights

Study Summary

This trial tests if it's possible to collect DNA from blood samples to test before and after cancer treatment.

Who is the study for?

This trial is for adults over 18 with diffuse large B-cell lymphoma (DLBCL) needing treatment. Participants must be able to give written consent and should not be pregnant or cognitively impaired. The study aims to include a diverse group from community centers across Texas.Check my eligibility

What is being tested?

The trial is exploring the use of cell-free DNA (cfDNA) as a tool to detect genetic changes in DLBCL patients and monitor minimal residual disease after treatment. cfDNA samples are taken from blood drawn through vein puncture before and after therapy.See study design

What are the potential side effects?

There are generally no direct side effects associated with providing a blood sample for cfDNA analysis, but some individuals may experience minor discomfort, bruising, or bleeding at the puncture site.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion; an average 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion; an average 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion; an average 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival (OS)

Trial Design

1Treatment groups

Experimental Treatment

Group I: cell-free DNA (cfDNA) samplesExperimental Treatment1 Intervention

cell-free DNA (cfDNA) samples from DLBCL participants before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Blood will be drawn 3 times (by vein)

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor

2,974 Previous Clinical Trials

1,788,959 Total Patients Enrolled

253 Trials studying Lymphoma

32,025 Patients Enrolled for Lymphoma

Christopher Flowers, MDPrincipal InvestigatorM.D. Anderson Cancer Center

3 Previous Clinical Trials

52 Total Patients Enrolled

3 Trials studying Lymphoma

52 Patients Enrolled for Lymphoma

Media Library

cell-free DNA (cfDNA) samples Clinical Trial Eligibility Overview. Trial Name: NCT05676450 — N/A

Lymphoma Research Study Groups: cell-free DNA (cfDNA) samples

Lymphoma Clinical Trial 2023: cell-free DNA (cfDNA) samples Highlights & Side Effects. Trial Name: NCT05676450 — N/A

cell-free DNA (cfDNA) samples 2023 Treatment Timeline for Medical Study. Trial Name: NCT05676450 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are involved in this research project?

"Affirmative. Clinicaltrial.gov data indicates that this experiment, which was first uploaded on February 23rd 2023, is still actively recruiting participants. A total of 517 individuals are required to be recruited from one medical facility."

Answered by AI

Are any additional participants being taken for this research endeavor?

"Indeed, according to clinicaltrials.gov, the trial is currently recruiting patients and was originally posted on February 23rd 2023 with a recent update occurring on June 7th 2023. The study requires 517 participants from one hospital site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas

2023. "Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal Residual Disease for Lymphoma Patients Across Community Centers in Texas". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05676450.